STOCK TITAN

Medicenna Therapeutics Corp - MDNA STOCK NEWS

Welcome to our dedicated news page for Medicenna Therapeutics (Ticker: MDNA), a resource for investors and traders seeking the latest updates and insights on Medicenna Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Medicenna Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Medicenna Therapeutics's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.58%
Tags
clinical trial
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.58%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.63%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.04%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.41%
Tags
earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.01%
Tags
offering
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-46.6%
Tags
offering
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-46.6%
Tags
offering
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.28%
Tags
earnings
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.35%
Tags
clinical trial
Medicenna Therapeutics Corp

Nasdaq:MDNA

MDNA Rankings

MDNA Stock Data

Pharmaceutical Preparation Manufacturing
Manufacturing
Link

About MDNA

medicenna is a clinical stage immunotherapy company developing novel highly selective versions of il-2, il-4 and il-13 superkines and first in class empowered cytokines (ecs). our mission is to become the leader in the development and commercialization of targeted ecs and superkines for the treatment of a broad range of cancers and immune-mediated diseases. we seek to achieve these successful treatments by drawing on our expertise, and that of world-class collaborators, to develop a unique set of superkines. these superkines can be developed either on their own as short or long-acting therapeutics or fused with pro-apoptotic proteins in order to precisely deliver potent cell-killing agents to the cancer cells as well as the immunosuppressive tumor micro-environment and the cancer stem cells without harming healthy cells. superkines can also be fused with other types of proteins such as antibodies to generate novel “immunocytokines” or combined with other treatment modalities such as ca